Fig. 3
Overall survival (OS) of patients with HER2-overexpression uterine serous carcinoma who were treated with CP or CP + T. CP, carboplatin plus paclitaxel; T: trastuzumab
Fig. 3 | BMC Medicine
Overall survival (OS) of patients with HER2-overexpression uterine serous carcinoma who were treated with CP or CP + T. CP, carboplatin plus paclitaxel; T: trastuzumab